Q&A Session at 2022 Annual General Meeting
Imagion Biosystems recording of the Q&A session at the 2022 Annual General Meeting. Imagion Biosystems’ board of directors answer questions from shareholders at the AGM
Imagion Biosystems recording of the Q&A session at the 2022 Annual General Meeting. Imagion Biosystems’ board of directors answer questions from shareholders at the AGM
In accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001, Imagion Biosystems Limited advises the results of its Annual General
The presentation visuals from the 25th May 2022 Annual General Meeting are now available. You can find the 2022 AGM Investor Presentation here. Other
Imagion Biosystems recording and transcript of the Chairman’s address to shareholders at the 2022 Annual General Meeting. Dear Shareholders, It is my pleasure to
Imagion has released the Quarterly Activity Report and Appendix 4C for the period ending on 31 March 2022. The announcement highlights: MagSense® HER2 breast cancer
We are pleased to provide our investors with our April 2022 Investor Newsletter. In this edition, our Chief Financial Officer, Geoff Hollis, gives a recap
Imagion Biosystems Limited (ASX: IBX) is pleased to provide an update on the progress of its first-in-human study for the MagSense® HER2 breast cancer imaging
Imagion Biosystems has released its Annual Report for the year ended 31 December 2021. See linked documents below. 2021 Clinical Highlights: Multiple patients enrolled and
Imagion has released the Quarterly Activity Report and Appendix 4C for the period ending on 31 December 2021. The announcement highlights a recap of the
The document “Application for quotation of +securities” was lodged with ASX on 6th January, 2022. Please click to review the full announcement at ASX.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance